LAG3 and melanoma: Relatlimab was the first anti-LAG-3 mAb that entered clinical testing, as a monotherapy or combination therapy with nivolumab, an anti-PD-1 mAb, in melanoma, renal cell carcinoma, and non–small cell lung carcinoma (NCT019680109).